Tradestie Institutional Equity Comparison Engine

KTTA vs BFRI โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

KTTA Overall Edge

KTTA Captures Institutional Edge (2โ€“1 Pillars ยท 5โ€“4 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Pasithea Therapeutics Corp. Common Stock (KTTA) driven by superior Growth & Margin, Momentum & Technical while BFRI counters with relative strength in Valuation. Fundamentally, KTTA trades at N/M Forward P/E with 0.0% operating margin (+1498.1% YoY revenue) versus BFRI at 13.0x Forward P/E and -12.6% operating margin (+29.8% YoY). In options structure, KTTA sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against BFRI sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner BFRI
KTTA N/M vs BFRI 13.0x Fwd P/E
Growth & Margin Winner KTTA
Op Margin 0.0% vs -12.6% ยท YoY +1498.1% vs +29.8%
Momentum & Technical Winner KTTA
1Y +0.6% vs -34.5% ยท 52W Pos 11% vs 0%
Options & Structure Winner Tie
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (N/A IV)
KTTA NASDAQ
Pasithea Therapeutics Corp. Common Stock
Pharmaceutical Preparations
$0.48
-0.48% 1D
Market Cap $17.7M
1M Return +7.52%
1Y Return +0.59%
Forward P/E N/M
Unified AI Score
42.1 / 100 HOLD
Tech 20.0 Fund 40.0 Flow 50.0 Mom 60.0
BFRI NASDAQ
Biofrontera Inc. Common Stock
Pharmaceutical Preparations
$0.53
-7.02% 1D
Market Cap $10.2M
1M Return -32.14%
1Y Return -34.49%
Forward P/E 13.0x
Unified AI Score
44.0 / 100 HOLD
Tech 25.0 Fund 42.0 Flow 50.0 Mom 59.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: KTTA +0.59% BFRI -34.49% Spread: +35.08 pp (KTTA Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period KTTA Revenue BFRI Revenue KTTA Op. Margin BFRI Op. Margin Margin Edge
FY2020 N/A $20M N/A -51.0% BFRI
FY2021 $0M $20M -29925.7% -104.6% BFRI
FY2022 $0M $30M -2587.3% -64.8% BFRI
FY2023 N/A $30M N/A -66.6% BFRI
FY2024 N/A $40M N/A -46.1% BFRI
FY2025 N/A $40M N/A -27.2% BFRI

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: KTTA (5) vs BFRI (4)
Institutional Metric KTTA BFRI Criterion Row Winner
Market Capitalization Scale $17.7M $10.2M Larger Scale Tie
Trailing P/E Ratio Valuation N/M 13.0x Lower Multiple BFRI
Forward P/E Ratio Valuation N/M 13.0x Lower Multiple BFRI
Revenue Growth (YoY) Growth +1498.1% +29.8% Higher Growth KTTA
Operating Margin (TTM) Profitability 0.0% -12.6% Higher Margin KTTA
Net Profit Margin Profitability 0.0% -12.7% Higher Margin KTTA
Return on Equity (ROE) Capital Efficiency -88.8% -988.4% Higher ROE KTTA
52-Week Range Position Momentum 11% ($0โ€“$2) 0% ($1โ€“$2) Stronger Trend KTTA
Beta / 30D Volatility Risk Regime 0.68ฮฒ ยท 185% Vol 1.84ฮฒ ยท 125% Vol Lower Realized Risk BFRI
Unified Institutional Score Composite Signal 42.1 / 100 (HOLD) 44.0 / 100 (HOLD) Higher Composite BFRI

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full KTTA vs BFRI Buy Guide
KTTA UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live KTTA Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
BFRI UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live BFRI Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither KTTA nor BFRI registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.